- See Also
-
Links
- “Drug Release Profile of a Novel Exenatide Long-Term Drug Delivery System (OKV-119) Administered to Cats”, Klotsman et al 2024
- “Functional and Multi-Omic Aging Rejuvenation With GLP-1R Agonism”, Huang et al 2024
- “Trial of Lixisenatide in Early Parkinson’s Disease”, Meissner et al 2024
- “Is Target-Based Drug Discovery Efficient? Discovery and ‘Off-Target’ Mechanisms of All Drugs”, Sadri 2023
- “Efficacy and Safety of Oral Orforglipron in Patients With Type 2 Diabetes: a Multicenter, Randomized, Dose-Response, Phase 2 Study”, Frias et al 2023b
- “Patents and Regulatory Exclusivities on GLP-1 Receptor Agonists”, Alhiary et al 2023
- “Evaluation of Out-Of-Pocket Costs and Treatment Intensification With an SGLT2 Inhibitor or GLP-1 RA in Patients With Type 2 Diabetes & Cardiovascular Disease”, Luo et al 2023
- “Medicare Part D Coverage of Antiobesity Medications—Challenges and Uncertainty Ahead”, Baig et al 2023
- “The Effects of Switching from Dipeptidyl Peptidase-4 Inhibitors to Glucagon-Like Peptide-1 Receptor Agonists on Bone Mineral Density in Diabetic Patients”, Huang et al 2023
- “The Gut-Bone Axis in Diabetes”, Maagensen et al 2022
- “Safety and Efficacy Assessment of a GLP-1 Mimetic: Insulin Glargine Combination for Treatment of Feline Diabetes Mellitus”, Scuderi et al 2018
- “Targeting the GIPR for Obesity: To Agonize or Antagonize? Potential Mechanisms”, Campbell 2012
- “The GLP-1 Mimetic Exenatide Potentiates Insulin Secretion in Healthy Cats”, Gilor et al 2011
- “Normalization of Fasting Hyperglycemia by Exogenous Glucagon-Like Peptide 1 (7-36 Amide) in Type 2 (non-Insulin-Dependent) Diabetic Patients”, Nauck et al 1993
- “Effect of Truncated Glucagon-Like Peptide-1 [Proglucagon-(78-107) Amide] on Endocrine Secretion from Pig Pancreas, Antrum, and Nonantral Stomach”, Ørskov et al 1988
- “Could Danuglipron Be the Next Ozempic in Pill Form?”
- “GLP-1 Receptor Agonists and Colorectal Cancer Risk in Drug-Naive Patients With Type 2 Diabetes, With and Without Overweight/Obesity”
- “Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes”
- “Safety, Tolerability, and Proof-Of-Concept Study of OKV-119, a Novel Exenatide Long-Term Drug Delivery System, in Healthy Cats”
- “Doctors Test the Limits of What Obesity Drugs Can Fix”
- Wikipedia
- Miscellaneous
- Bibliography
See Also
Links
“Drug Release Profile of a Novel Exenatide Long-Term Drug Delivery System (OKV-119) Administered to Cats”, Klotsman et al 2024
“Functional and Multi-Omic Aging Rejuvenation With GLP-1R Agonism”, Huang et al 2024
Functional and multi-omic aging rejuvenation with GLP-1R agonism
“Trial of Lixisenatide in Early Parkinson’s Disease”, Meissner et al 2024
“Is Target-Based Drug Discovery Efficient? Discovery and ‘Off-Target’ Mechanisms of All Drugs”, Sadri 2023
Is Target-Based Drug Discovery Efficient? Discovery and ‘Off-Target’ Mechanisms of All Drugs
“Efficacy and Safety of Oral Orforglipron in Patients With Type 2 Diabetes: a Multicenter, Randomized, Dose-Response, Phase 2 Study”, Frias et al 2023b
“Patents and Regulatory Exclusivities on GLP-1 Receptor Agonists”, Alhiary et al 2023
Patents and Regulatory Exclusivities on GLP-1 Receptor Agonists
“Evaluation of Out-Of-Pocket Costs and Treatment Intensification With an SGLT2 Inhibitor or GLP-1 RA in Patients With Type 2 Diabetes & Cardiovascular Disease”, Luo et al 2023
“Medicare Part D Coverage of Antiobesity Medications—Challenges and Uncertainty Ahead”, Baig et al 2023
Medicare Part D Coverage of Antiobesity Medications—Challenges and Uncertainty Ahead:
View PDF:
“The Effects of Switching from Dipeptidyl Peptidase-4 Inhibitors to Glucagon-Like Peptide-1 Receptor Agonists on Bone Mineral Density in Diabetic Patients”, Huang et al 2023
“The Gut-Bone Axis in Diabetes”, Maagensen et al 2022
“Safety and Efficacy Assessment of a GLP-1 Mimetic: Insulin Glargine Combination for Treatment of Feline Diabetes Mellitus”, Scuderi et al 2018
“Targeting the GIPR for Obesity: To Agonize or Antagonize? Potential Mechanisms”, Campbell 2012
Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms
“The GLP-1 Mimetic Exenatide Potentiates Insulin Secretion in Healthy Cats”, Gilor et al 2011
The GLP-1 mimetic exenatide potentiates insulin secretion in healthy cats
“Normalization of Fasting Hyperglycemia by Exogenous Glucagon-Like Peptide 1 (7-36 Amide) in Type 2 (non-Insulin-Dependent) Diabetic Patients”, Nauck et al 1993
“Effect of Truncated Glucagon-Like Peptide-1 [Proglucagon-(78-107) Amide] on Endocrine Secretion from Pig Pancreas, Antrum, and Nonantral Stomach”, Ørskov et al 1988
“Could Danuglipron Be the Next Ozempic in Pill Form?”
“GLP-1 Receptor Agonists and Colorectal Cancer Risk in Drug-Naive Patients With Type 2 Diabetes, With and Without Overweight/Obesity”
“Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes”
“Safety, Tolerability, and Proof-Of-Concept Study of OKV-119, a Novel Exenatide Long-Term Drug Delivery System, in Healthy Cats”
“Doctors Test the Limits of What Obesity Drugs Can Fix”
Wikipedia
Miscellaneous
-
/doc/longevity/glp/2017-schneider.pdf:View PDF:
-
https://edition.cnn.com/2024/05/08/health/ozempic-babies-pregnancy/index.html -
https://journals.sagepub.com/doi/full/10.1177/1098612X16660441 -
https://marginalrevolution.com/marginalrevolution/2024/07/the-economics-of-glp-1.html -
https://trevorklee.substack.com/p/glp-1-and-gip-agonism-and-antagonism -
https://www.annualreviews.org/content/journals/10.1146/annurev-med-043021-014919
Bibliography
-
https://bmcvetres.biomedcentral.com/articles/10.1186/s12917-024-04051-6: “Drug Release Profile of a Novel Exenatide Long-Term Drug Delivery System (OKV-119) Administered to Cats”, -
2023-sadri.pdf: “Is Target-Based Drug Discovery Efficient? Discovery and ‘Off-Target’ Mechanisms of All Drugs”, -
2023-frias-2.pdf: “Efficacy and Safety of Oral Orforglipron in Patients With Type 2 Diabetes: a Multicenter, Randomized, Dose-Response, Phase 2 Study”,